CD133 is also useful in predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer [27], suggesting that CD133 expression may be of help in more accurately predicting the aggressive properties and in determining the optimal therapeutic strategy for this neoplasia. This evidence concerns the gene PROM1 and breast carcinoma.